Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MetaViaMTVA +4.23%30 5-Year Yield-on-Cost % is 0.00 as of Aug. 04, 2026. GuruFocus rates MTVA with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 150 Biotechnology companies, MetaVia ranks worse than 666666% on this metric.
MetaVia's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for MetaVia's 5-Year Yield-on-Cost % or its related term are showing as below:
MTVA's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.69 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
MetaVia 5-Year Yield-on-Cost % Related Terms
MTVA vs CNSP, TRAW, APRE: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, MetaVia's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MetaVia 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MetaVia's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where MetaVia's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of MetaVia is calculated as
MetaVia (MTVA) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 04, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on MetaVia and its competitors. According to the industry distribution chart, MetaVia ranks #999999 out of 150 companies in the Biotechnology industry.
Is MetaVia's 5-Year Yield-on-Cost % too high?
MetaVia's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, MetaVia ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MetaVia has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does MetaVia's 5-Year Yield-on-Cost % compare to CNSP and TRAW?
According to the Biotechnology industry distribution chart, MetaVia ranks #999999 out of 150 companies for 5-Year Yield-on-Cost %. This places MetaVia in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.69, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on MetaVia and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MetaVia's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaVia stock overvalued right now?
MetaVia (MTVA) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. MetaVia's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For MetaVia (MTVA), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
30GF Score
Get the complete analysis for MTVA
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MTVA has been successfully added to your 
